You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股表現》宜明昂科(01541.HK)暗盤高開7.5%報20元 現升12.4%
根據輝立交易平台顯示,明天掛牌的宜明昂科-B(01541.HK)暗盤高開7.5%報20元,高低見21.1元/19.4元,現報20.9元,較上市價18.6元,高12.4%,成交5.6萬股。 來自上海的宜明昂科是一家臨床階段的生物技術公司,致力於開發腫瘤免疫療法。是次以每股18.6元來港上市合共發售1,714.72萬股,並已引入包括Harvest、藥明生物(02269.HK)旗下Wuxi Venture、榮昌生物(09995.HK)子公司及昆翎4名基石投資者,合共認購1,248.52萬股;10%公開發售獲近9倍超購,認購一手中籤率11.56%,料集資淨額約2.345億元,當中約40%及28%將分別用於核心產品IMM01,以及核心產品IMM0306、IMM2902和IMM2520正在進行和計劃開展的臨床試驗、籌備註冊申請以及計劃的商業化上市;約10%將用於IMM47 (CD24單克隆抗體)計劃開展的臨床試驗。上市聯席保薦人分別為大摩及中金。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account